Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00336063
- Locations
- 🇸🇬
National University Hospital Singapore, Singapore, Singapore
🇯🇵National Cancer Center Hospital, Tokyo, Japan
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
- Conditions
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 69
- Registration Number
- NCT00321711
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARAAlkylating Agent-Related Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 197
- Registration Number
- NCT00313586
- Locations
- 🇺🇸
Clements University Hospital, Dallas, Texas, United States
🇺🇸Union Hospital of Cecil County, Elkton, Maryland, United States
🇺🇸Hematology and Oncology Associates, Chicago, Illinois, United States
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00234000
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00118287
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Conditions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 1
- Registration Number
- NCT00118196
- Locations
- 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
- First Posted Date
- 2005-02-01
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 151
- Registration Number
- NCT00102687
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Research Department, Bakersfield, California, United States
🇺🇸Great Lakes Cancer Institute Breslin Cancer Center, Lansing, Michigan, United States
🇺🇸Greater Dayton Cancer Center, Kettering, Ohio, United States
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00101179
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
- Conditions
- Locations
- 🇺🇸
Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-12-16
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT00005598
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.